# 00_DataAnalysis.md: Modular Microbiome Analysis Pipeline

## üéØ Project Intent

This is a **modular, flexible pipeline** for microbiome analysis in Multiple Myeloma (MM) patients undergoing autologous stem cell transplant (ASCT). The pipeline allows researchers to **choose and combine different analysis components** based on their specific research questions and data characteristics.

## üìä Pipeline Architecture

The pipeline is designed with **maximum flexibility**, allowing you to select from multiple options at each stage:

```
Data Sources ‚Üí Data Curation ‚Üí Extreme Points ‚Üí Microbial Grouping ‚Üí Variable Selection ‚Üí Variable Grouping ‚Üí Group Selection ‚Üí MVA Correlation ‚Üí Output Generation ‚Üí Population Analysis ‚Üí Timepoints Comparison
    ‚Üì              ‚Üì              ‚Üì                     ‚Üì                    ‚Üì                ‚Üì                ‚Üì                ‚Üì              ‚Üì                     ‚Üì                        ‚Üì
File Selection  Quality Control  Patient Subset       Choose 1+            Choose 1+        Choose 1+        Choose 1+        Choose 1+      Choose 1+             Choose 1+                 Choose 1+
& Validation   & Integration    Selection            Categories            Discard Methods  Grouping Methods Discard Methods  Correlation     Output Types          Stratification            Cross-Timepoint
```

## üìã Modular Pipeline Components

### **Phase 1: 01_DataSourcesSelect.md - Data Source Selection**
**When:** Very beginning - establishes data foundation
**Choice:** Select and validate core data files
- Patient metadata, taxonomy mappings, microbial abundance data
**Purpose:** Ensure data compatibility and establish analysis foundation

### **Phase 2: 02_DataCuration.md - Data Import and Quality Control**
**When:** After data source selection - before any analysis
**Choice:** Select data import methods and quality control procedures
- Raw data import, metadata curation, quality control, normalization, etc.
**Purpose:** Ensure data quality and prepare for downstream analysis

### **Phase 3: 03_ExtremePointsSelection.md - Extreme Time Points Selection**
**When:** After data curation - focuses analysis scope
**Choice:** Select extreme outcome patients for targeted analysis
- Percentage-based selection by time variables or patient counts
**Purpose:** Concentrate on patients with most extreme clinical outcomes

### **Phase 4: 04_MicrobialGrouping.md - Microbial Category Selection**
**When:** After extreme points selection - defines biological focus
**Choice:** Select one or more microbial functional categories
- SCFA Producers, Pathogenic Bacteria, Immunomodulators, etc.
**Purpose:** Narrow analysis to biologically relevant microbes from the start

### **Phase 5: 05_VariableSelection.md - Variable Selection/Discard**
**When:** After microbial grouping - reduce dimensionality
**Choice:** Select one or multiple variable discard methods
- PFS-aware screening, prevalence filtering, variance selection, etc.
**Purpose:** Remove noise and irrelevant variables while preserving signal

### **Phase 6: 06_VariableGrouping.md - Variable Grouping**
**When:** After variable selection - organize remaining variables
**Choice:** Select one or more grouping methods
- Functional pathways, taxonomic hierarchy, correlation clustering, etc.
**Purpose:** Create biologically meaningful composite variables

### **Phase 7: 07_GroupSelection.md - Group Selection/Discard**
**When:** After variable grouping - refine grouped variables
**Choice:** Select one or multiple group discard methods
- PFS screening, stability selection, multivariate filtering, etc.
**Purpose:** Keep only the most relevant grouped variables for analysis

### **Phase 8: 08_MVAMethods.md - Multivariate PFS Correlation**
**When:** Final analysis - establish statistical relationships
**Choice:** Select one or multiple correlation methods
- Cox regression, PLS, random forests, neural networks, etc.
**Purpose:** Find robust correlations between microbial groups and PFS

### **Phase 9: 09_OutputOptions.md - Output Information Generation**
**When:** After analysis - present results
**Choice:** Select one or multiple output types
- Statistical reports, visualization plots, interactive dashboards, etc.
**Purpose:** Generate comprehensive, interpretable results for different audiences

### **Phase 10: 10_PopulationSubgroupsComparison.md - Population Subgroups Analysis**
**When:** After output generation - advanced subgroup analysis
**Choice:** Select subgroup analysis methods for within-timepoint/delta comparisons
- Clinical/demographic subgroup definitions, stratified analysis approaches
**Purpose:** Identify subgroup-specific microbial effects within selected timepoint/delta

### **Phase 11: 11_TimePointsComparison.md - Timepoints Comparison**
**When:** After multiple timepoint/delta analyses - cross-timepoint synthesis
**Choice:** Compare results across different timepoints and deltas
- Cross-timepoint effect testing, trajectory analysis, clinical recommendations
**Purpose:** Identify timepoint-specific vs universal microbial biomarkers

## üîÑ Workflow Flexibility

### **Linear Path (Recommended for Beginners):**
```
Choose 1 method per phase ‚Üí Execute in order ‚Üí Generate outputs
```

### **Exploratory Path (Recommended for Advanced Users):**
```
Choose multiple methods per phase ‚Üí Compare results ‚Üí Select best combinations ‚Üí Generate comprehensive outputs
```

### **Custom Path (Maximum Flexibility):**
```
Mix and match methods across phases ‚Üí Test different combinations ‚Üí Optimize for your specific research question
```

## üéØ Expected Outcomes by Research Focus

### **Clinical Biomarker Discovery:**
- **Recommended Combination:** SCFA Producers ‚Üí PFS-aware selection ‚Üí Pathway grouping ‚Üí Cox regression ‚Üí Statistical reports + Clinical decision tools
- **Expected Output:** PFS risk scores, clinical validation metrics, patient stratification tools
- **Timeline:** 2-3 months with existing methods
- **Resource Needs:** Moderate computational requirements

### **Mechanistic Understanding:**
- **Recommended Combination:** Immunomodulators ‚Üí Functional pathways ‚Üí Correlation clustering ‚Üí Random forests ‚Üí Interactive visualizations + Biological pathway maps
- **Expected Output:** Biological pathway maps, interaction networks, mechanistic hypotheses
- **Timeline:** 3-4 months with mixed implemented/suggested methods
- **Resource Needs:** High computational requirements for ML methods

### **Comprehensive Analysis:**
- **Recommended Combination:** Multiple microbial categories ‚Üí Multiple selection methods ‚Üí Multiple grouping approaches ‚Üí Multiple MVA methods ‚Üí All output types
- **Expected Output:** Complete analysis package for publication, meta-analysis framework
- **Timeline:** 4-6 months with extensive method development
- **Resource Needs:** Very high computational and development requirements

### **Quick Exploratory Analysis:**
- **Recommended Combination:** Any microbial category ‚Üí Prevalence filtering ‚Üí Taxonomic grouping ‚Üí Univariate screening ‚Üí Statistical reports + Basic visualizations
- **Expected Output:** Initial findings, hypothesis generation
- **Timeline:** 1-2 weeks with existing methods
- **Resource Needs:** Low computational requirements

## üìà Success Metrics

### **Method Selection Quality:**
- **Biological relevance:** Methods align with research hypotheses
- **Statistical validity:** Appropriate for data characteristics
- **Computational feasibility:** Reasonable resource requirements
- **Interpretability:** Results understandable to domain experts

### **Pipeline Performance:**
- **Reproducibility:** Same choices produce consistent results
- **Scalability:** Works with different dataset sizes
- **Modularity:** Easy to modify individual components
- **Integration:** Components work well together

### **Research Impact:**
- **Clinical translation:** Results inform patient care
- **Biological insights:** Novel mechanisms discovered
- **Methodological advances:** New analysis approaches validated

## üìä Method Implementation Status

### **Currently Available Methods:**
- **Data Source Selection:** 6 timepoint/delta options (all implemented)
- **Data Curation:** 7 methods (6 implemented, 1 suggested)
- **Extreme Points Selection:** 2 selection modes (all implemented)
- **Microbial Grouping:** 11 categories (all available)
- **Variable Selection:** 7 methods (3 implemented, 4 suggested)
- **Variable Grouping:** 7 methods (1 implemented, 6 suggested)
- **Group Selection:** 7 methods (all suggested)
- **MVA Methods:** 6 methods (1 implemented, 5 suggested)
- **Output Options:** 10 formats (all suggested)
- **Population Subgroups:** 8 stratification methods (all suggested)
- **TimePoints Comparison:** 4 comparison methods (all suggested)

### **Development Priority Recommendations:**
1. **High Priority (Foundation):** Complete data curation pipeline, PFS-aware selection methods, advanced extreme points algorithms
2. **Medium Priority:** Advanced MVA methods, additional grouping approaches, clinical decision tools
3. **Low Priority:** Specialized output formats, meta-analysis frameworks, automated data source validation

## üõ†Ô∏è Technical Implementation

### **Core Technologies:**
- **Programming:** Python 3.8+
- **Key Libraries:** lifelines, scikit-learn, pandas, numpy, matplotlib, seaborn
- **Data Formats:** CSV, TSV, BIOM (for microbiome data)
- **Metadata:** Clinical data with PFS outcomes

### **Quality Assurance:**
- **Input validation:** Check data formats and completeness
- **Parameter validation:** Ensure method parameters are appropriate
- **Output verification:** Validate results make biological sense
- **Reproducibility:** Random seed control for stochastic methods

### **Scalability Considerations:**
- **Memory management:** Efficient data structures for large datasets
- **Parallel processing:** Utilize multiple cores when possible
- **Incremental processing:** Process data in chunks for very large datasets
- **Caching:** Save intermediate results to avoid recomputation

## üéØ Innovation Aspects

### **Modular Design:**
- **Component independence:** Each method can be swapped without affecting others
- **Method agnostic:** Pipeline works with any combination of compatible methods
- **Extensibility:** Easy to add new methods to any phase

### **Biological Integration:**
- **Function-first approach:** Start with biological relevance, not statistics
- **Context awareness:** Methods consider clinical and biological context
- **Mechanistic focus:** Enable discovery of biological mechanisms

### **User-Centric Design:**
- **Choice flexibility:** Researchers can tailor pipeline to their needs
- **Result customization:** Generate outputs appropriate for different audiences
- **Educational value:** Learn about different analysis approaches

## üîß Practical Guidance

### **Method Selection Strategy:**
1. **Start with your research question:** Choose microbial categories that align with your hypotheses
2. **Consider data characteristics:** Select methods appropriate for your sample size and data quality
3. **Balance complexity vs. interpretability:** More complex methods may provide better performance but harder interpretation
4. **Plan for computational resources:** Some methods require significant computing power
5. **Think about validation:** Choose methods that can be properly validated with your data

### **Common Pitfalls to Avoid:**
- **Method overkill:** Don't use complex methods when simpler ones suffice
- **Ignoring biological context:** Statistical significance doesn't equal biological relevance
- **PFS-unaware selection:** Always prioritize clinical relevance over pure statistical criteria
- **Single method reliance:** Validate findings across multiple complementary approaches
- **Output mismatch:** Choose outputs that match your target audience's needs

### **Quality Control Checkpoints:**
- **After data curation:** Verify data integrity, normalization appropriateness, and sample matching
- **After microbial grouping:** Verify selected taxa are detectable in your dataset
- **After variable selection:** Check that biologically important taxa aren't discarded
- **After grouping:** Ensure groups are biologically interpretable
- **After MVA:** Validate that correlations make clinical sense
- **Before outputs:** Ensure results are reproducible and robust

### **Scaling Considerations:**
- **Small datasets (n<50):** Focus on robust data curation, implemented methods, avoid overfitting-prone approaches
- **Medium datasets (n=50-200):** Can use more complex methods, implement cross-validation, comprehensive quality control
- **Large datasets (n>200):** Suitable for machine learning approaches, extensive validation, and automated curation pipelines

This modular pipeline represents a comprehensive, flexible framework for microbiome analysis that adapts to different research questions while maintaining scientific rigor and biological relevance. The structured approach ensures reproducible, clinically meaningful results across diverse study designs and objectives.